268 related articles for article (PubMed ID: 22053288)
1. Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look.
Whatcott CJ; Han H; Posner RG; Hostetter G; Von Hoff DD
Cancer Discov; 2011 Sep; 1(4):291-6. PubMed ID: 22053288
[TBL] [Abstract][Full Text] [Related]
2. Dose- and time-dependent effects of hyaluronidase on structural cells and the extracellular matrix of the skin.
Buhren BA; Schrumpf H; Gorges K; Reiners O; Bölke E; Fischer JW; Homey B; Gerber PA
Eur J Med Res; 2020 Nov; 25(1):60. PubMed ID: 33228813
[TBL] [Abstract][Full Text] [Related]
3. Sugars in the microenvironment: the sticky problem of HA turnover in tumors.
Schmaus A; Bauer J; Sleeman JP
Cancer Metastasis Rev; 2014 Dec; 33(4):1059-79. PubMed ID: 25324146
[TBL] [Abstract][Full Text] [Related]
4. Property and current clinical applications of mammal hyaluronidase.
Lv SH; Rong SF; Cai BG; Guan SM; Li QQ
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(20):3968-76. PubMed ID: 26531287
[TBL] [Abstract][Full Text] [Related]
5. CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion.
Bourguignon LY; Singleton PA; Diedrich F; Stern R; Gilad E
J Biol Chem; 2004 Jun; 279(26):26991-7007. PubMed ID: 15090545
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy.
Singha NC; Nekoroski T; Zhao C; Symons R; Jiang P; Frost GI; Huang Z; Shepard HM
Mol Cancer Ther; 2015 Feb; 14(2):523-32. PubMed ID: 25512619
[TBL] [Abstract][Full Text] [Related]
7. Aberrant serum hyaluronan and hyaluronidase levels in scleroderma.
Neudecker BA; Stern R; Connolly MK
Br J Dermatol; 2004 Mar; 150(3):469-76. PubMed ID: 15030329
[TBL] [Abstract][Full Text] [Related]
8. The cell surface hyaluronidase TMEM2 regulates cell adhesion and migration via degradation of hyaluronan at focal adhesion sites.
Irie F; Tobisawa Y; Murao A; Yamamoto H; Ohyama C; Yamaguchi Y
J Biol Chem; 2021; 296():100481. PubMed ID: 33647313
[TBL] [Abstract][Full Text] [Related]
9. Purification of hyaluronidase as an anticancer agent inhibiting CD44.
Shakouri A; Parvan R; Adljouy N; Abdolalizadeh J
Biomed Chromatogr; 2020 Jan; 34(1):e4709. PubMed ID: 31630417
[TBL] [Abstract][Full Text] [Related]
10. Plasma hyaluronidase (Hyal-1) promotes tumor cell cycling.
Lin G; Stern R
Cancer Lett; 2001 Feb; 163(1):95-101. PubMed ID: 11163112
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronan and Collagen Are Prominent Extracellular Matrix Components in Bovine and Porcine Ovaries.
Parkes WS; Amargant F; Zhou LT; Villanueva CE; Duncan FE; Pritchard MT
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440360
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models.
Thompson CB; Shepard HM; O'Connor PM; Kadhim S; Jiang P; Osgood RJ; Bookbinder LH; Li X; Sugarman BJ; Connor RJ; Nadjsombati S; Frost GI
Mol Cancer Ther; 2010 Nov; 9(11):3052-64. PubMed ID: 20978165
[TBL] [Abstract][Full Text] [Related]
13. COPD Exacerbations Are Associated With Proinflammatory Degradation of Hyaluronic Acid.
Papakonstantinou E; Roth M; Klagas I; Karakiulakis G; Tamm M; Stolz D
Chest; 2015 Dec; 148(6):1497-1507. PubMed ID: 26226411
[TBL] [Abstract][Full Text] [Related]
14. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2.
Harada H; Takahashi M
J Biol Chem; 2007 Feb; 282(8):5597-607. PubMed ID: 17170110
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.
Ekici S; Cerwinka WH; Duncan R; Gomez P; Civantos F; Soloway MS; Lokeshwar VB
Int J Cancer; 2004 Oct; 112(1):121-9. PubMed ID: 15305383
[TBL] [Abstract][Full Text] [Related]
16. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview.
Girish KS; Kemparaju K
Life Sci; 2007 May; 80(21):1921-43. PubMed ID: 17408700
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).
Wong KM; Horton KJ; Coveler AL; Hingorani SR; Harris WP
Curr Oncol Rep; 2017 Jul; 19(7):47. PubMed ID: 28589527
[TBL] [Abstract][Full Text] [Related]
18. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis.
Kramer MW; Escudero DO; Lokeshwar SD; Golshani R; Ekwenna OO; Acosta K; Merseburger AS; Soloway M; Lokeshwar VB
Cancer; 2011 Mar; 117(6):1197-209. PubMed ID: 20960509
[TBL] [Abstract][Full Text] [Related]
19. Forced expression of KIAA1199, a novel hyaluronidase, inhibits tumorigenicity of low-grade chondrosarcoma.
Koike H; Nishida Y; Shinomura T; Zhuo L; Hamada S; Ikuta K; Ito K; Kimata K; Ushida T; Ishiguro N
J Orthop Res; 2020 Sep; 38(9):1942-1951. PubMed ID: 32068299
[TBL] [Abstract][Full Text] [Related]
20. Murine hyaluronidase 2 deficiency results in extracellular hyaluronan accumulation and severe cardiopulmonary dysfunction.
Chowdhury B; Hemming R; Hombach-Klonisch S; Flamion B; Triggs-Raine B
J Biol Chem; 2013 Jan; 288(1):520-8. PubMed ID: 23172227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
